Why the MDT question matters for oligodendroglioma
Oligodendroglioma sits at the intersection of neurosurgery, neuropathology, neuro-oncology and radiation oncology. The diagnosis depends on tumour tissue plus molecular markers, and the treatment plan depends on what has already been done and what remains possible. A single clinic visit may not resolve all of those threads at once.
That is why families ask about a multidisciplinary team (MDT) discussion. The useful question is not simply whether the hospital has an MDT. It is what a joint discussion would actually decide in this case, and what happens if the hospital does not run one in that format.
Assessment of an adult central nervous system tumour considers tumour type, site and grade along with the patient's circumstances, and treatment decisions are individual. This is the frame for every question below: the discussion is about this patient's tumour and history, not a generic protocol.
The diagnostic questions an MDT must resolve first
Before any treatment sequencing can be discussed, the team needs to agree on what the tumour actually is. For a suspected or confirmed oligodendroglioma, that means the histology report and the molecular reports, particularly IDH status and 1p/19q codeletion status. If those results exist, the discussion should confirm they are complete and internally consistent. If they do not exist, the discussion should state what tissue or testing is still needed and who will arrange it.
Ask directly: does the pathology report include the molecular markers needed to classify this tumour, and has a neuropathologist reviewed the slides rather than only the written summary? If the original slides are available, a pathology re-review can be part of the discussion. If they are not, say so and ask what the team can conclude without them.
A second question is whether the imaging has been reviewed jointly. Tumour site and extent influence what is technically feasible, and a neuroradiologist's reading of the same scans can differ from a summary in a referral letter. Ask whether imaging review is part of the meeting or a separate step.
Finally, ask what remains uncertain after the records are reviewed. A good MDT output names its own limits: what is confirmed, what is probable, and what cannot be answered without more information. That is more useful than a plan presented as certain when the file is incomplete.
Prior treatment: what the discussion needs to reconstruct
Treatment sequencing for a glioma depends heavily on what has already happened. The MDT needs a clear timeline: when the tumour was first identified, what surgery was performed and what the operative and pathology reports said, whether radiation therapy was given and to what area, and which systemic treatments were used, at what dose and for how long.
This is often where overseas records are thinnest. A discharge summary may say 'chemotherapy completed' without naming the regimen, cycles or reason for stopping. Ask the treating team what specific documents they need to reconstruct the timeline, then request those documents from the original hospital. If a record genuinely cannot be obtained, tell the team rather than leaving a gap they will interpret as no treatment.
Ask the MDT to state explicitly how prior treatment changes the options. For example, whether a previously irradiated area limits further radiation, or whether a prior regimen affects what can be offered now. You do not need to propose a regimen yourself; you need the discussion to explain its reasoning about your history.
One practical point: bring a one-page timeline in English, with dates, procedures, drugs and outcomes. It does not replace the source documents, but it helps the team see the sequence quickly and ask better follow-up questions.
Sequencing questions the MDT should answer in plain terms
Sequencing is the core of the discussion. The team should be able to say, in order, what it recommends next, what alternatives exist, and what would change the recommendation. If surgery is being considered, the discussion should address the goal of surgery, the expected extent of resection and the functional risks given the tumour's location. If radiation or systemic therapy is being considered, the discussion should address timing relative to surgery and any prior treatment.
Ask what the recommendation depends on. A plan that hinges on a pending molecular result, a repeat scan or a functional assessment is provisional, and the team should say so. Ask what the trigger would be for changing course, and who would make that decision.
Ask how the team handles disagreement between specialties. In a genuine MDT, the neurosurgeon, pathologist, radiation oncologist and medical oncologist may weigh the same evidence differently. The useful output is a documented consensus or a clearly stated split, not a single opinion presented as the whole team's view.
Ask what the patient's own priorities can change. If avoiding a specific side effect matters more than a marginal difference in approach, the discussion should say whether that preference is compatible with the recommended sequence or whether it points to an alternative.
What to ask when no formal MDT is available
Not every hospital runs a formal joint meeting for every case, and no hospital is obliged to provide one in a particular format. That does not mean the questions disappear. It means you need to ask how the equivalent input is obtained.
Ask whether the specialists communicate through a joint meeting, a shared review of records, or sequential consultations with a coordinating clinician. Ask who holds overall responsibility for the plan and who you should contact with a follow-up question. If the answer is a single treating physician, ask how that physician obtains pathology, imaging and radiation oncology input.
If a formal meeting is not offered, ask whether the records can be reviewed by more than one relevant specialty before a decision is made. This is a reasonable request, and the answer tells you how the hospital actually works. It also tells you whether travelling before that review is worthwhile.
Be cautious about any promise of a specific meeting format, a named specialist or a guaranteed joint review. Those are hospital decisions. What you can ask for is a written statement of how the plan was reached and which specialties contributed.
Records to prepare and how to phrase the request
The quality of an MDT discussion depends on the records in front of it. For an oligodendroglioma case, the core set is the pathology report with molecular markers, the operative report, the most recent imaging with the radiologist's report, radiation therapy records if applicable, and a medication and treatment history with dates. Add any genetic or molecular reports, and a current list of symptoms and functional concerns.
When you contact a hospital or a coordination service, phrase the request around the decision rather than the diagnosis alone. A useful message says: the diagnosis is oligodendroglioma, these reports are available, prior treatment was X, and the question is whether a multidisciplinary review can address diagnosis confirmation, sequencing and the alternatives. That gives the team something to route.
Ask what the review will produce. A written summary, a clinic note, or a verbal discussion each has different value for a patient deciding whether to travel. Ask who writes it, in what language, and whether it will state the team's reasoning and its uncertainties.
Keep the initial enquiry short. A brief summary and a list of available documents is enough to start; detailed records can follow once the team confirms what it needs. Do not send passport numbers, payment details or a complete archive in a first message.
Next step
Start by assembling the pathology report with molecular markers, the operative report, recent imaging and a dated treatment history. Then send a short enquiry describing the diagnosis, what records exist and the specific question you want a multidisciplinary discussion to answer. An initial enquiry is free and does not require buying a proxy consultation; the hospital decides whether and how a review can be arranged.
If the case is complex or spans several specialties, a records-based multidisciplinary review can be discussed with the scope and fee agreed in advance. The relevant reference for the surgical side of glioma care is linked below. Keep the decision in your hands: ask what the review will answer, what it cannot answer, and what the treating team still needs to confirm.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.